Can a Delaware resident get peptides by telehealth?
Title 24, chapter 60 of the Delaware Code (enacted by 83 Del. Laws, c. 52) sets telehealth rules for the listed health professions. Section 6001 defines telemedicine to include secure video conferencing and store and forward transfer, and defines store and forward transfer as a synchronous or asynchronous transmission of a patient's medical information that does not require the patient to be present or to be in real time. Section 6003(a) requires a health-care provider-patient relationship, which may be established in person or through telehealth and must include verifying the patient's location and identity, disclosing the provider's identity and credentials, obtaining consent, establishing a diagnosis through acceptable medical practices, and giving the patient a written visit summary. Section 6003(b) says telehealth services may be synchronous or asynchronous using store-and-forward technology, and may be used to establish the relationship only if the provider determines the provider can meet the same standard of care as an in-person visit. Section 6003(c) prohibits issuing a prescription solely in response to an internet questionnaire, an internet consult, or a telephone consult in the absence of a proper relationship. Section 6004(a) adds that before diagnosis and treatment the provider must do at least one of the following: examine the patient in person, have another Delaware-licensed provider present with the patient, make the diagnosis using audio or visual communication, or meet professional society guidelines for establishing a relationship in evidence-based telemedicine practice. A provider licensed in a state without an applicable interstate compact may treat Delaware patients by telehealth only with an interstate telehealth registration from the Division of Professional Regulation. This record classifies asynchronous prescribing as allowed because section 6003(b) expressly permits asynchronous store-and-forward services and lets telehealth establish the relationship. A prescription issued solely from an internet questionnaire without a proper relationship is prohibited. [2] [3] [4]
How does the Delaware pharmacy board treat compounding?
| Board | Delaware Board of Pharmacy (Division of Professional Regulation) |
|---|---|
| Eligible substances | Follows the federal 503A framework |
The Delaware Board of Pharmacy licenses pharmacies under Title 24, chapter 25 of the Delaware Code and its Board regulations. Delaware has no separate state bulks list, so peptide eligibility follows the federal 503A framework (approved drug component, USP or NF monograph, or FDA 503A bulks list). Chapter 25 was reorganized by 85 Del. Laws chapter 49, effective June 30, 2026; in the current Delaware Code, checked 2026-09-22, a pharmacy in another state that delivers, dispenses, or distributes a prescription drug to a Delaware patient must hold a Delaware nonresident pharmacy license (section 2535), which requires good standing in every state where it is licensed and the most recent Board-approved inspection report covering the business it will conduct in Delaware, performed by or for its home-state licensing authority (or, if the home state has not inspected, by a national pharmacy verification program or another qualified entity). It must designate a Delaware registered agent (section 2536), keep a valid home-state license, and may be disciplined for failing to send the Board later inspection reports within 60 days of receiving them (section 2537). The Board's regulations (24 Del. Admin. Code 2500) require all compounding to comply with section 503A of the federal act (regulation 5.1.6) and require every Board licensee that compounds to comply with USP chapters 795 and 797 (regulation 10.0). [1] [5] [6] [7] [9]
Can you get compounded GLP-1s in Delaware?
Delaware patients using an out-of-state telehealth GLP-1 program should confirm the prescriber is Delaware-licensed or holds an interstate telehealth registration, and that the pharmacy holds a Delaware nonresident pharmacy license. [4] [6] [12]
Prices by channel: semaglutide cost, tirzepatide cost.
Approvals, shortage history, and prices for every GLP-1 we track are on the GLP-1 hub.
What is the legal access path in Delaware?
Access options
Prescriber licensed in Delaware, in person or by telehealth
Telehealth prescribing of non-controlled peptides is permitted in Delaware. A prescriber may prescribe without a live visit (asynchronous care) when it meets the standard of care. State law says an online questionnaire alone is not enough.
Check the dispensing pharmacy against the board's license lookup before paying, including out-of-state mail-order pharmacies.
Branded GLP-1 through a retail or manufacturer pharmacy
FDA approved semaglutide and tirzepatide are available by prescription. Compounded GLP-1 limited; see the GLP-1 section for why.
CJC-1295 / Ipamorelin from Bodybuilding Peptides
SponsoredPartner lists from $220/month
Tesamorelin / Ipamorelin from Bodybuilding Peptides
SponsoredPartner lists from $274/month
Semax / Selank from Bodybuilding Peptides
SponsoredPartner lists from $274/month
We may earn a commission from these links.
Prices are the partner's own and are not verified by PeptideAgent. You answer health questions after checkout, and the partner's clinician decides whether to prescribe.
Unsponsored access paths are checked against public regulatory records. Sponsored offers are the partner's and are labeled. Products labeled research use only are never listed.
Find a provider in Delaware
What you'll actually find in Delaware, and how to check
Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. [16] [17] [18]
No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [19]
What Delaware has done
PeptideAgent has not found a board or legislative action on peptides in Delaware.
Other states have acted:
- On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [21] Mississippi law
- Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [22] [23] Louisiana law
Checking the prescriber
Telehealth prescribing of non-controlled peptides is permitted in Delaware. A prescriber may prescribe without a live visit (asynchronous care) when it meets the standard of care. State law says an online questionnaire alone is not enough. [2] [3] [4] The telehealth rule in full.
Checking the pharmacy
Look the pharmacy up yourself before you pay, including an out-of-state mail-order pharmacy. The pharmacy regulator is the Delaware Board of Pharmacy (Division of Professional Regulation); its license search: FDA BeSafeRx: state board of pharmacy license lookups. [20]
If you're going ahead anyway
These steps lower some risks. They do not make a compounded product safe, and FDA has not reviewed it. [19]
They do not change a peptide's legal status either. That depends on the peptide: for a withdrawn nomination such as BPC-157 or TB-500, a 503A pharmacy has no federal basis to compound it from bulk, with or without a prescription, while a few Category 1 substances, such as NAD+ and glutathione, are compounded under FDA's interim policy, with conditions. Each peptide page gives its status. [10] [24] [25]
Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [20] [26] [27]
What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [18] [27] [28]
Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [19] [29] [30] [31] [32] [33]
Check for:
- A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [19]
- A real evaluation by a licensed prescriber, not just an online form.
- A certificate of analysis for the specific batch.
Questions to ask
- Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [20]
- Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [18]
- Pharmacy: Is this made for me on a prescription written in my name? [28]
- Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [18] [27]
- Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [18]
What is offered for a specific peptide, and what FDA found, is on each peptide page.
Is it legal to buy research peptides in Delaware?
Only Delaware-licensed pharmacies and licensed nonresident pharmacies may dispense prescription drugs to Delaware patients. "Research use only" peptides sold for human injection are unapproved new drugs under federal law, are not dispensed by a pharmacist, and fall outside Delaware's pharmacy licensing system. Delaware's own food and drug law (16 Del. C. chapter 33, Pure Food and Drugs) prohibits manufacturing or selling an adulterated or misbranded drug (section 3302) but has no separate new-drug approval provision, so the prohibition on selling unapproved new drugs comes from federal law. [6] [8] [13]
Peptide-specific notes for Delaware
| Peptide | Note |
|---|---|
| Semaglutide | Available branded by prescription through telehealth under 24 Del. C. chapter 60, including from out-of-state physicians with a Delaware interstate telehealth registration. Compounded semaglutide is limited to documented patient-specific needs since the 503A grace period ended April 22, 2025. [2] [4] [12] |
Frequently asked questions
Can an out-of-state telehealth doctor prescribe me a GLP-1 in Delaware?
Yes, if the physician holds a Delaware license or a Delaware interstate telehealth registration. Under 24 Del. C. 6002(c), a provider licensed in a state that has not adopted an applicable interstate compact may give telehealth in Delaware only with an interstate telehealth registration from the Division of Professional Regulation. To qualify, the provider must hold an active license in good standing in every state where licensed and must not face a pending complaint or investigation. The provider must still establish a provider-patient relationship under 24 Del. C. 6003. [2] [4]
Can I get a prescription in Delaware just by filling out an online form?
Not without a proper provider-patient relationship. Section 6003 bars issuing a prescription solely in response to an internet questionnaire, internet consult, or telephone consult when no relationship has been established, and the relationship requires identity and location verification and disclosure of the provider's credentials. Section 6004(a) also requires, before diagnosis and treatment, an in-person exam, another Delaware-licensed provider present with you, a diagnosis made by audio or visual communication, or compliance with professional society guidelines for evidence-based telemedicine. [2]
What does an out-of-state pharmacy need to ship compounded peptides to Delaware?
A Delaware nonresident pharmacy license. The pharmacy must also designate a Delaware registered agent, keep its home-state license valid, and send the Board of Pharmacy its inspection reports. Check the Division of Professional Regulation license lookup before ordering. [1] [6]
Can a Delaware pharmacy compound BPC-157?
Only under a draft federal policy, and only within strict limits. On October 28, 2026 HHS released a draft enforcement discretion policy saying it will not take enforcement action against a state-licensed pharmacy that compounds BPC-157 as a single-ingredient product by an allowed route, on a patient-specific prescription, from an FDA-registered manufacturer's substance with a tested certificate of analysis, with serious adverse events reported to FDA. BPC-157 is still not FDA approved or on the 503A bulks list, the policy is not binding and HHS may revisit it, and blends such as Wolverine are not covered. FDA's drug center recommended against listing BPC-157; the advisory committee voted in favor (HHS policy, Appendix B). State law still applies: Delaware has no separate state bulks list, so peptide eligibility follows the federal 503A framework. [10] [11] [14] [15]
Sources
Numbered citations above point to these primary sources: the state statute or rule, the pharmacy board, federal FDA guidance, and the FDA warning letters and studies behind what is offered.
- [1]Delaware Board of Pharmacy, Division of Professional Regulation
- [2]Delaware Code Title 24, chapter 60, Provisions applicable to telehealth and telemedicine
- [3]24 Del. C. 6003, Scope of practice; provider-patient relationship required
- [4]Delaware Division of Professional Regulation: medical interstate telehealth registrations
- [5]Delaware Code Title 24, chapter 25, Pharmacy
- [6]Delaware Code Title 24, chapter 25, subchapter IV, Pharmacies (nonresident pharmacy sections 2535 to 2537)
- [7]Delaware Administrative Code Title 24, 2500 Board of Pharmacy regulations (5.1.6 Compounding; 10.0 Pharmaceutical Compounding), accessed 2026-09-22
- [8]Delaware Code Title 16, chapter 33, Pure Food and Drugs (section 3302), accessed 2026-09-22
- [9]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
- [10]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B category lists)FDA
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, October 28). Are peptides legal in Delaware?. https://peptideagent.ai/legal/delaware- HTML link
<a href="https://peptideagent.ai/legal/delaware">Are peptides legal in Delaware?</a>, PeptideAgent, updated October 28, 2026.